Doni Bloomfield

Associate Law Professor @FordhamLawNYC

[Jeff Gordon @jeffgordon12]

I have a new essay up at @lawfare with @DoniBloomfield. We argue that current export control policy is in a worst-of-both-worlds trap: bad for protecting technology, and bad for U.S. innovation. But there is a solution, of course! https://t.co/lMISkWA8Ow.

[Doni Bloomfield @DoniBloomfield]

@lawfare And our complete argument is in our recent working paper: https://t.co/NM27GOo2P0

[Doni Bloomfield @DoniBloomfield]

Why is US export control policy so scattershot--ramping up controls one month, only to scale them back the next? Jeff Gordon and I argue in @lawfare that the coalition to support controls is unstable: developers no longer rely on US govt R&D, but many do count on exports

[Doni Bloomfield @DoniBloomfield]

@lawfare The whole piece is here: https://t.co/YliQXblQMr

[Lawfare @lawfare]

The White House's export policy has resulted in a paradoxical AI policy. @DoniBloomfield and Jeff Gordon explain why protecting the United States’ technological advantage has become more costly and what can be done to make export controls less self-destructive.

[Doni Bloomfield @DoniBloomfield]

@statnews And we need US soft power more than ever to confront the biosecurity dangers posed by AI models, synthetic cells, the possibility of mirror life, and more. Full paper is here: https://t.co/RAKjRavkyq

[Doni Bloomfield @DoniBloomfield]

New from me today in @statnews: why the Trump admin's attempt to politicize science grantmaking could not only hurt US science, but also make it harder to tackle pressing risks such as the biosecurity risks posed by AI https://t.co/MeAXbpWZZB

[Doni Bloomfield @DoniBloomfield]

@statnews Others have persuasively argued that making grantmaking partisan will harm US science. History suggests an additional surprising result. Doing so will crush the connections between NIH and scientists, and erode the NIH's ability to pilot key regulations with expert input

[Jeff Gordon @jeffgordon12]

New draft paper with @DoniBloomfield: "The New Export-Control Equilibrium." Export controls are arguably the central legal tool of US-China competition. Yet legal scholarship has barely touched them. https://t.co/GmmlLvqEO7

[Doni Bloomfield @DoniBloomfield]

@ScienceMagazine A big thanks to coauthors @JassiPannuMD @jrm_black @OllyMCrook @BrandesNadav @Moritz_Hanke @T_Inglesby Anita Cicero Robert Pollack @tmboussard Michael Imperiale and @Rbaltman for helping this come together.

[Doni Bloomfield @DoniBloomfield]

New article out today in @ScienceMagazine on safeguarding novel biological data that could help AI systems design enhanced viruses. We draw on privacy law & biosafety to propose a new framework for regulating the most concerning data while allowing scientists to forge ahead

[Jassi Pannu @JassiPannuMD]

Today in @ScienceMagazine , we propose a first-of-its-kind framework to safeguard access to the biological data that could teach AI systems to design pandemic pathogens.

AI models are dependent on data. Unfettered access to data has served science well. Should this change? 🧵

[Doni Bloomfield @DoniBloomfield]

@davidmanheim @LongResilience @JassiPannuMD @anita_cicero Yes, now there is! https://t.co/l788x306Ie

[Alan Rozenshtein @ARozenshtein]

In @lawfare, @petersalib, Doni Bloomfield and I explain why AI safety laws California's SB 1047 generally don't present First Amendment issues. Whether they're good or bad policy is a different question. https://t.co/bIhh3KOpPU

[Doni Bloomfield @DoniBloomfield]

As we argue, on day 1 Biden can help fix this by (1) reversing a series of PTO memos that make rejecting patents harder, (2) giving examiners more time to do their jobs properly, and (3) starting to wean the agency off of fees it only gets when it grants a patent 10/10

[Doni Bloomfield @DoniBloomfield]

Whatever happens today in Georgia, Joe Biden can act to lower drug prices and increase invention—new from me and @akesselheim in @washingtonpost today https://t.co/DGfDohE9UA 1/n

[Doni Bloomfield @DoniBloomfield]

For context, a single protein immunology drug—Humira��brought in $12 billion in US sales in 2017, or more than twice as much as the entire domestic fish harvest 9/n